The receptor tyrosine kinase ROR1 - An oncofetal antigen for targeted cancer therapy

Seminars in Cancer Biology

Volumn 29, Issue C, 2014, Pages 21-31

  Hojjat Farsangi, Mohammad ^a   Moshfegh, Ali ^a   Daneshmanesh, Amir Hossein ^a   Khan, Abdul Salam ^a   Mikaelsson, Eva ^a   Österborg, Anders ^a   Mellstedt, Håkan ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cancer therapy; Monoclonal antibodies; ROR1; Tyrosine kinase inhibitors

Indexed keywords

CETUXIMAB; CIRMTUZUMAB; ERLOTINIB; GEFITINIB; GEMCITABINE; IMMUNOTOXIN; LAPATINIB; LENALIDOMIDE; MONOCLONAL ANTIBODY; ONCOFETAL ANTIGEN; PERTUZUMAB; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RECEPTOR TYROSINE KINASE ROR1; TRASTUZUMAB; UNCLASSIFIED DRUG; ISOPROTEIN; ONCOFETAL ANTIGENS; PROTEIN KINASE INHIBITOR; RECEPTOR TYROSINE KINASE LIKE ORPHAN RECEPTOR; ROR1 PROTEIN, HUMAN; TUMOR ANTIGEN;

ACTIVE IMMUNIZATION; BREAST CANCER; CANCER THERAPY; CELL SURVIVAL; CENTRAL NERVOUS SYSTEM; CHRONIC LYMPHATIC LEUKEMIA; DRUG TARGETING; EMBRYO DEVELOPMENT; ENZYME ACTIVITY; ENZYME STRUCTURE; HEART; HUMAN; LUNG; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; MOLECULARLY TARGETED THERAPY; NONHUMAN; PANCREAS CARCINOMA; PROTEIN EXPRESSION; REVIEW; SKELETON; TUMOR CELL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; GENETICS; IMMUNOLOGY; METABOLISM; NEOPLASMS; PATHOLOGY;

ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; EMBRYONIC DEVELOPMENT; HUMANS; IMMUNOTHERAPY, ACTIVE; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTEIN ISOFORMS; PROTEIN KINASE INHIBITORS; RECEPTOR TYROSINE KINASE-LIKE ORPHAN RECEPTORS;

EID: 84927578271     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2014.07.005     Document Type: Review

References (109)

1. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
2. Tsai C.J., Nussinov R. The molecular basis of targeting protein kinases in cancer therapeutics. Semin Cancer Biol 2013, 23:235-242.
3. Weinstein I.B. Disorders in cell circuitry during multistage carcinogenesis: the role of homeostasis. Carcinogenesis 2000, 21:857-864.
4. Shah D.R., Shah R.R., Morganroth J. Tyrosine kinase inhibitors: their on-target toxicities as potential indicators of efficacy. Drug Saf 2013, 36:413-426.
5. Krause D.S., Van Etten R.A. Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005, 353:172-187.
6. Tsai C.J., Nussinov R. The molecular basis of targeting protein kinases in cancer therapeutics. Semin Cancer Biol 2013, 23:235-242.
7. Masiakowski P., Carroll R.D. A novel family of cell surface receptors with tyrosine kinase-like domain. J Biol Chem 1992, 267:26181-26190.
8. Wilson C., Goberdhan D.C., Steller H. Dror a potential neurotrophic receptor gene, encodes a Drosophila homolog of the vertebrate Ror family of Trk-related receptor tyrosine kinases. Proc Natl Acad Sci U S A 1993, 90:7109-7113.
9. Gschwind A., Fischer O.M., Ullrich A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer 2004, 4:361-370.
10. Blume-Jensen P., Hunter T. Oncogenic kinase signalling. Nature 2001, 411:355-365.
11. Ullrich A., Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell 1990, 61:203-212.
12. Robinson D.R., Wu Y.M., Lin S.F. The protein tyrosine kinase family of the human genome. Oncogene 2000, 19:5548-5557.
13. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000, 103:211-225.
14. Lemmon M.A., Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2010, 141:1117-1134.
15. Haglund K., Rusten T.E., Stenmark H. Aberrant receptor signaling and trafficking as mechanisms in oncogenesis. Crit Rev Oncog 2007, 13:39-74.
16. Abella J.V., Park M. Breakdown of endocytosis in the oncogenic activation of receptor tyrosine kinases. Am J Physiol Endocrinol Metab 2009, 296:E973-E984.
17. Takeuchi K., Ito F. Receptor tyrosine kinases and targeted cancer therapeutics. Biol Pharm Bull 2011, 34:1774-1780.
18. Oishi I., Sugiyama S., Liu Z.J., Yamamura H., Nishida Y., Minami Y. A novel Drosophila receptor tyrosine kinase expressed specifically in the nervous system. Unique structural features and implication in developmental signaling. J Biol Chem 1997, 272:11916-11923.
19. Oishi I., Takeuchi S., Hashimoto R., Nagabukuro A., Ueda T., Liu Z.J., et al. Spatio-temporally regulated expression of receptor tyrosine kinases, mRor1, mRor2, during mouse development: implications in development and function of the nervous system. Genes Cells 1999, 4:41-56.
20. Forrester W.C., Dell M., Perens E., Garriga G. A C. elegans Ror receptor tyrosine kinase regulates cell motility and asymmetric cell division. Nature 1999, 400:881-885.
21. Reddy U.R., Phatak S., Pleasure D. Human neural tissues express a truncated Ror1 receptor tyrosine kinase, lacking both extracellular and transmembrane domains. Oncogene 1996, 13:1555-1559.
22. Forrester W.C. The Ror receptor tyrosine kinase family. Cell Mol Life Sci 2002, 59:83-96.
23. Yoda A., Oishi I., Minami Y. Expression and function of the Ror-family receptor tyrosine kinases during development: lessons from genetic analyses of nematodes, mice, and humans. J Recept Signal Transduct Res 2003, 23:1-15.
24. Minami Y., Oishi I., Endo M., Nishita M. Ror-family receptor tyrosine kinases in noncanonical Wnt signaling: their implications in developmental morphogenesis and human diseases. Dev Dyn 2010, 239:1-15.
25. Hanks S.K., Quinn A.M. Protein kinase catalytic domain sequence database: identification of conserved features of primary structure and classification of family members. Methods Enzymol 1991, 200:38-62.
26. Hanks S.K., Quinn A.M., Hunter T. The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. Science 1988, 241:42-52.
27. Pearson R.B., Kemp B.E. Protein kinase phosphorylation site sequences and consensus specificity motifs: tabulations. Methods Enzymol 1991, 200:62-81.
28. Hojjat-Farsangi M., Khan A.S., Daneshmanesh A.H., Moshfegh A., Sandin A., Mansouri L., et al. The tyrosine kinase receptor ROR1 is constitutively phosphorylated in chronic lymphocytic leukemia (CLL) cells. PLOS ONE 2013, 8:e78339.
29. Gentile A., Lazzari L., Benvenuti S., Trusolino L., Comoglio P.M. The ROR1 pseudokinase diversifies signaling outputs in MET-addicted cancer cells. Int J Cancer 2014, [in press].
30. Daneshmanesh A.H., Hojjat-Farsangi M., Khan A.S., Jeddi-Tehrani M., Akhondi M.M., Bayat A.A., et al. Monoclonal antibodies against ROR1 induce apoptosis of chronic lymphocytic leukemia (CLL) cells. Leukemia 2012, 26:1348-1355.
31. Huttlin E.L., Jedrychowski M.P., Elias J.E., Goswami T., Rad R., Beausoleil S.A., et al. A tissue-specific atlas of mouse protein phosphorylation and expression. Cell 2010, 143:1174-1189.
32. Songyang Z., Cantley L.C. Recognition and specificity in protein tyrosine kinase-mediated signalling. Trends Biochem Sci 1995, 20:470-475.
33. Pawson T. Protein modules and signalling networks. Nature 1995, 373:573-580.
34. Roskoski R. Src kinase regulation by phosphorylation and dephosphorylation. Biochem Biophys Res Commun 2005, 331:1-14.
35. Kuriyan J., Cowburn D. Modular peptide recognition domains in eukaryotic signaling. Annu Rev Biophys Biomol Struct 1997, 26:259-288.
36. Green J.L., Kuntz S.G., Sternberg P.W. Ror receptor tyrosine kinases: orphans no more. Trends Cell Biol 2008, 18:536-544.
37. Paganoni S., Ferreira A. Expression and subcellular localization of Ror tyrosine kinase receptors are developmentally regulated in cultured hippocampal neurons. J Neurosci Res 2003, 73:429-440.
38. Fukuda T., Chen L., Endo T., Tang L., Lu D., Castro J.E., et al. Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a. Proc Natl Acad Sci U S A 2008, 105:3047-3052.
39. Oishi I., Suzuki H., Onishi N., Takada R., Kani S., Ohkawara B., et al. The receptor tyrosine kinase Ror2 is involved in non-canonical Wnt5a/JNK signalling pathway. Genes Cells 2003, 8:645-654.
40. Mikels A.J., Nusse R. Purified Wnt5a protein activates or inhibits beta-catenin-TCF signaling depending on receptor context. PLoS Biol 2006, 4:e115.
41. Kim C., Forrester W.C. Functional analysis of the domains of the C. elegans Ror receptor tyrosine kinase CAM-1. Dev Biol 2003, 264:376-390.
42. Gentile A., Lazzari L., Benvenuti S., Trusolino L., Comoglio P.M. Ror1 is a pseudokinase that is crucial for Met-driven tumorigenesis. Cancer Res 2011, 71:3132-3141.
43. Yamaguchi T., Yanagisawa K., Sugiyama R., Hosono Y., Shimada Y., Arima C., et al. NKX2-1/TITF1/TTF-1-induced ROR1 is required to sustain EGFR survival signaling in lung adenocarcinoma. Cancer Cell 2012, 21:348-361.
44. Matsuda T., Nomi M., Ikeya M., Kani S., Oishi I., Terashima T., et al. Expression of the receptor tyrosine kinase genes, Ror1 and Ror2, during mouse development. Mech Dev 2001, 105:153-156.
45. Al-Shawi R., Ashton S.V., Underwood C., Simons J.P. Expression of the Ror1 and Ror2 receptor tyrosine kinase genes during mouse development. Dev Genes Evol 2001, 211:161-171.
46. Nomi M., Oishi I., Kani S., Suzuki H., Matsuda T., Yoda A., et al. Loss of mRor1 enhances the heart and skeletal abnormalities in mRor2-deficient mice: redundant and pleiotropic functions of mRor1 and mRor2 receptor tyrosine kinases. Mol Cell Biol 2001, 21:8329-8335.
47. Paganoni S., Ferreira A. Neurite extension in central neurons: a novel role for the receptor tyrosine kinases Ror1 and Ror2. J Cell Sci 2005, 118:433-446.
48. Baskar S., Kwong K.Y., Hofer T., Levy J.M., Kennedy M.G., Lee E., et al. Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia. Clin Cancer Res 2008, 14:396-404.
49. Hudecek M., Schmitt T.M., Baskar S., Lupo-Stanghellini M.T., Nishida T., Yamamoto T.N., et al. The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. Blood 2010, 116:4532-4541.
50. DeChiara T.M., Kimble R.B., Poueymirou W.T., Rojas J., Masiakowski P., Valenzuela D.M., et al. Ror2, encoding a receptor-like tyrosine kinase, is required for cartilage and growth plate development. Nat Genet 2000, 24:271-274.
51. Takeuchi S., Takeda K., Oishi I., Nomi M., Ikeya M., Itoh K., et al. Mouse Ror2 receptor tyrosine kinase is required for the heart development and limb formation. Genes Cells 2000, 5:71-78.
52. McKay S.E., Hislop J., Scott D., Bulloch A.G., Kaczmarek L.K., Carew T.J., et al. Aplysia ROR forms clusters on the surface of identified neuroendocrine cells. Mol Cell Neurosci 2001, 17:821-841.
53. Paganoni S., Bernstein J., Ferreira A. Ror1-Ror2 complexes modulate synapse formation in hippocampal neurons. Neuroscience 2010, 165:1261-1274.
54. Daneshmanesh A.H., Mikaelsson E., Jeddi-Tehrani M., Bayat A.A., Ghods R., Ostadkarampour M., et al. Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy. Int J Cancer 2008, 123:1190-1195.
55. Nishita M., Yoo S.K., Nomachi A., Kani S., Sougawa N., Ohta Y., et al. Filopodia formation mediated by receptor tyrosine kinase Ror2 is required for Wnt5a-induced cell migration. J Cell Biol 2006, 175:555-562.
56. Ren D., Minami Y., Nishita M. Critical role of Wnt5a-Ror2 signaling in motility and invasiveness of carcinoma cells following Snail-mediated epithelial-mesenchymal transition. Genes Cells 2011, 16:304-315.
57. Rosenwald A., Alizadeh A.A., Widhopf G., Simon R., Davis R.E., Yu X., et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001, 194:1639-1647.
58. Klein U., Tu Y., Stolovitzky G.A., Mattioli M., Cattoretti G., Husson H., et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med 2001, 194:1625-1638.
59. Shabani M., Asgarian-Omran H., Vossough P., Sharifian R.A., Faranoush M., Ghragozlou S., et al. Expression profile of orphan receptor tyrosine kinase (ROR1) and Wilms' tumor gene 1 (WT1) in different subsets of B-cell acute lymphoblastic leukemia. Leuk Lymphoma 2008, 49:1360-1367.
60. Shabani M., Asgarian-Omran H., Jeddi-Tehrani M., Vossough P., Faranoush M., Sharifian R.A., et al. Overexpression of orphan receptor tyrosine kinase Ror1 as a putative tumor-associated antigen in Iranian patients with acute lymphoblastic leukemia. Tumour Biol 2007, 28:318-326.
61. Rabbani H., Ostadkarampour M., Danesh Manesh A.H., Basiri A., Jeddi-Tehrani M., Forouzesh F. Expression of ROR1 in patients with renal cancer-a potential diagnostic marker. Iran Biomed J 2010, 14:77-82.
62. Zhang S., Chen L., Cui B., Chuang H.Y., Yu J., Wang-Rodriguez J., et al. ROR1 is expressed in human breast cancer and associated with enhanced tumor-cell growth. PLOS ONE 2012, 7:e31127.
63. Hojjat-Farsangi M., Ghaemimanesh F., Daneshmanesh A.H., Bayat A.A., Mahmoudian J., Jeddi-Tehrani M., et al. Inhibition of the receptor tyrosine kinase ROR1 by anti-ROR1 monoclonal antibodies and siRNA induced apoptosis of melanoma cells. PLOS ONE 2013, 8:e61167.
64. O'Connell M.P., Marchbank K., Webster M.R., Valiga A.A., Kaur A., Vultur A., et al. Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2. Cancer Discov 2013, 3:1378-1393.
65. Shabani M., Asgarian Omran H., Farsangi M.H., Vossough P., Sharifian R.A., Toughe G.R., et al. Comparative expression profile of orphan receptor tyrosine kinase ROR1 in Iranian patients with lymphoid and myeloid leukemias. Avicenna J Med Biotechnol 2011, 3:119-125.
66. Daneshmanesh A.H., Porwit A., Hojjat-Farsangi M., Jeddi-Tehrani M., Tamm K.P., Grander D., et al. Orphan receptor tyrosine kinases ROR1 and ROR2 in hematological malignancies. Leuk Lymphoma 2013, 54:843-850.
67. Zhang S., Chen L., Wang-Rodriguez J., Zhang L., Cui B., Frankel W., et al. The onco-embryonic antigen ROR1 is expressed by a variety of human cancers. Am J Pathol 2012, 181:1903-1910.
68. Pieters R., Carroll W.L. Biology and treatment of acute lymphoblastic leukemia. Pediatr Clin North Am 2008, 55:1-20. ix.
69. Dave H., Anver M.R., Butcher D.O., Brown P., Khan J., Wayne A.S., et al. Restricted cell surface expression of receptor tyrosine kinase ROR1 in pediatric B-lineage acute lymphoblastic leukemia suggests targetability with therapeutic monoclonal antibodies. PLOS ONE 2012, 7:e52655.
70. Bicocca V.T., Chang B.H., Masouleh B.K., Muschen M., Loriaux M.M., Druker B.J., et al. Crosstalk between ROR1 and the Pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia. Cancer Cell 2012, 22:656-667.
71. Yang J., Baskar S., Kwong K.Y., Kennedy M.G., Wiestner A., Rader C. Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies. PLoS ONE 2011, 6:e21018.
72. Barna G., Mihalik R., Timar B., Tombol J., Csende Z., Sebestyen A., et al. ROR1 expression is not a unique marker of CLL. Hematol Oncol 2011, 29:17-21.
73. Cui B., Zhang S., Chen L., Yu J., Widhopf G.F., Fecteau J.F., et al. Targeting ROR1 inhibits epithelial-mesenchymal transition and metastasis. Cancer Res 2013, 73:3649-3660.
74. Tseng H.C., Lyu P.C., Lin W.C. Nuclear localization of orphan receptor protein kinase (Ror1) is mediated through the juxtamembrane domain. BMC Cell Biol 2010, 11:48.
75. Li P., Harris D., Liu Z., Liu J., Keating M., Estrov Z. Stat3 activates the receptor tyrosine kinase like orphan receptor-1 gene in chronic lymphocytic leukemia cells. PLoS ONE 2010, 5:e11859.
76. Hazan-Halevy I., Harris D., Liu Z., Liu J., Li P., Chen X., et al. STAT3 is constitutively phosphorylated on serine 727 residues, binds DNA, and activates transcription in CLL cells. Blood 2010, 115:2852-2863.
77. Kaucka M., Krejci P., Plevova K., Pavlova S., Prochazkova J., Janovska P., et al. Post-translational modifications regulate signalling by Ror1. Acta Physiol (Oxf) 2011, 203:351-362.
78. Mellstedt H., Daneshmanesh A.H., Moshfegh A., Hojjat-Farsangi M., Khan A.S., Mikaelsson E., et al. A new class of compound for pancreatic carcinoma targeting the tyrosine kinase receptor (TKR) ROR1. ASCO 50th annals meeting 2014, [Abstract No.: e13561].
79. Daneshmanesh A.H., Hojjat-Farsangi M., Moshfegh A., Mikaelsson E., Khan A.S., Österborg A., et al. Anti-ROR1 monoclonal antibodies induce apoptosis in pancreatic cancer cells via the PI3-kinase/AKT/mTOR pathway. AACR annual meeting 2014 2014, [Abstract No.: 4770].
80. Widhopf G.F., Cui B., Ghia E.M., Chen L., Messer K., Shen Z., et al. ROR1 can interact with TCL1 and enhance leukemogenesis in Emu-TCL1 transgenic mice. Proc Natl Acad Sci U S A 2014, 111:793-798.
81. Ghosh A.K., Secreto C., Boysen J., Sassoon T., Shanafelt T.D., Mukhopadhyay D., et al. The novel receptor tyrosine kinase Axl is constitutively active in B-cell chronic lymphocytic leukemia and acts as a docking site of nonreceptor kinases: implications for therapy. Blood 2011, 117:1928-1937.
82. Liu P.C., Liu X., Li Y., Covington M., Wynn R., Huber R., et al. Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cells. Cancer Biol Ther 2006, 5:657-664.
83. Graziano C. HER-2 breast assay, linked to Herceptin, wins FDA's okay. CAP Today 1998, 12(1):14-16.
84. Herbst R.S., Fukuoka M., Baselga J. Gefitinib-a novel targeted approach to treating cancer. Nat Rev Cancer 2004, 4:956-965.
85. Dowell J., Minna J.D., Kirkpatrick P. Erlotinib hydrochloride. Nat Rev Drug Discov 2005, 4:13-14.
86. Xia W., Mullin R.J., Keith B.R., Liu L.H., Ma H., Rusnak D.W., et al. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 2002, 21:6255-6263.
87. Rimawi M.F., Wiechmann L.S., Wang Y.C., Huang C., Migliaccio I., Wu M.F., et al. Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenografts. Clin Cancer Res 2011, 17:1351-1361.
88. Yuan H.H., Han Y., Bian W.X., Liu L., Bai Y.X. The effect of monoclonal antibody cetuximab (C225) in combination with tyrosine kinase inhibitor gefitinib (ZD1839) on colon cancer cell lines. Pathology 2012, 44:547-551.
89. Baselga J., Bradbury I., Eidtmann H., Di Cosimo S., de Azambuja E., Aura C., et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012, 379:633-640.
90. Guarneri V., Frassoldati A., Bottini A., Cagossi K., Bisagni G., Sarti S., et al. Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study. J Clin Oncol 2012, 30:1989-1995.
91. Anselmo A.C., Mitragotri S. An overview of clinical and commercial impacts of drug delivery systems. J Control Release 2014, [in press].
92. Baskar S., Wiestner A., Wilson W.H., Pastan I., Rader C. Targeting malignant B cells with an immunotoxin against ROR1. mAbs 2012, 4:349-361.
93. Widhopf I.I.G., Cui B., Ghia E., Chen L., Messer K., Shen Z., et al. ROR1 can interact with TCL1 and enhance leukemogenesis in Eμ-TCL1 transgenic mice. Blood (ASH Annual Meeting Abstracts) 2013, 122. [Abstract No.: 868].
94. Cui B., Widhopf I.I.G., Prussak C.E., Wu C., Sadarangani A., Zhang S., et al. Cirmtuzumab vedotin (UC-961ADC3), an anti-ROR1-monomethyl auristatin E antibody-drug conjugate, is a potential treatment for ROR1-positive leukemia and solid tumors. Blood (ASH Annual Meeting Abstracts) 2013, 122. [Abstract No.: 1637].
95. Mellstedt H., Khan S., Vågberg J., Byström s, Schultz J., Hojjat-Farsangi M., et al. Effect of ROR1-targeting small molecules on chronic lymphocytic leukemia (CLL) cells. J Clin Oncol 2012, 30(Suppl.). [Abstract No.: 6557].
96. Brown J.R. The treatment of relapsed refractory chronic lymphocytic leukemia. Hematol Am Soc Hematol Educ Program 2011, 2011:110-118.
97. Lapalombella R., Andritsos L., Liu Q., May S.E., Browning R., Pham L.V., et al. Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway. Blood 2010, 115:2619-2629.
98. Gonzalez-Rodriguez A.P., Payer A.R., Acebes-Huerta A., Huergo-Zapico L., Villa-Alvarez M., Gonzalez-Garcia E., et al. Lenalidomide and chronic lymphocytic leukemia. Biomed Res Int 2013, 2013:932010.
99. Gilbert J.A. Lenalidomide as first-line therapy for elderly CLL patients. Lancet Oncol 2013, 14:e345.
100. Hojjat-Farsangi M., Mozaffari F., Daneshmanesh A., Osterborg A., Shokri F., Mellstedt H., et al. Patients with chronic lymphocyte leukemia (CLL) have naturally occurring antibodies against the receptor tyrosine kinase (ROR1). Blood (ASH Annual Meeting Abstracts) 2011, 118. [Abstract No.: 1771].
101. Hojjat-Farsangi M., Daneshmanesh A., Jeddi-Tehrani M., Osterborg A., Shokri F., Mellstedt H., et al. T cells from CLL patients recognize spontaneously peptides derived of the receptor tyrosine kinase Ror1. Blood (ASH Annual Meeting Abstracts) 2010, 116. [Abstract No.: 3603].
102. Yu J., Cui B., Widhopf G.F., Chen L., Rassenti L., Wang Z., et al. Preclinical development of ROR1 peptide based vaccine with activity against chronic lymphocytic leukemia In ROR1 transgenic mice. Blood (ASH Annual Meeting Abstracts) 2013, 122. [Abstract No.: 4174].
103. Milani A., Sangiolo D., Montemurro F., Aglietta M., Valabrega G. Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives. Ann Oncol 2013, 24:1740-1748.
104. Sadelain M., Brentjens R., Riviere I. The promise and potential pitfalls of chimeric antigen receptors. Curr Opin Immunol 2009, 21:215-223.
105. Jena B., Dotti G., Cooper L.J. Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood 2010, 116:1035-1044.
106. Irving B.A., Weiss A. The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways. Cell 1991, 64:891-901.
107. Wieczorek A., Uharek L. Genetically modified T cells for the treatment of malignant disease. Transfus Med Hemother 2013, 40:388-402.
108. Carpenito C., Milone M.C., Hassan R., Simonet J.C., Lakhal M., Suhoski M.M., et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci U S A 2009, 106:3360-3365.
109. Hudecek M., Lupo-Stanghellini M.T., Kosasih P.L., Sommermeyer D., Jensen M.C., Rader C., et al. Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clin Cancer Res 2013, 19:3153-3164.